L3VLUP
ProSign in

BRKR · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BRKRLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BRKR
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterBRKRLLY
Q3 202010 holders, $2.2bn33 holders, $14.1bn
Q4 202010 holders, $3.0bn29 holders, $17.3bn
Q1 20218 holders, $3.6bn24 holders, $23.0bn
Q2 202114 holders, $4.3bn24 holders, $27.8bn
Q3 202118 holders, $4.2bn31 holders, $29.9bn
Q4 202115 holders, $4.1bn31 holders, $34.7bn
Q1 202213 holders, $3.0bn24 holders, $35.3bn
Q2 202214 holders, $2.9bn33 holders, $42.7bn
Q3 202214 holders, $1.7bn31 holders, $43.4bn
Q4 202210 holders, $2.0bn31 holders, $46.6bn
Q1 202312 holders, $2.1bn33 holders, $44.3bn
Q2 202312 holders, $2.0bn37 holders, $59.6bn
Q3 202311 holders, $1.4bn44 holders, $67.6bn
Q4 202313 holders, $1.7bn45 holders, $73.6bn
Q1 202410 holders, $2.1bn41 holders, $95.3bn
Q2 202410 holders, $1.7bn43 holders, $110bn
Q3 202410 holders, $1.8bn45 holders, $107bn
Q4 202412 holders, $1.4bn46 holders, $93.9bn
Q1 20259 holders, $817m42 holders, $98.4bn
Q2 20255 holders, $189m43 holders, $93.2bn
Q3 20257 holders, $123m39 holders, $86.7bn
Q4 20259 holders, $1.1bn41 holders, $123bn
Q1 20266 holders, $738m39 holders, $106bn
Q2 20269 holders, $1.8bn44 holders, $132bn
BRKR

Bruker Corp

Holders
10
Reported value
$2.1bn
Buyers
7
Sellers
4

Breadth +3 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
41
Reported value
$95.3bn
Buyers
15
Sellers
27

Breadth -12 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BRKR (4)

Farallon Capital Management LLC, PDT Partners LLC, Tudor Investment Corp, Voloridge Investment Management LLC

Only LLY (35)

Acadian Asset Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, and 10 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →